There are known research works about combined therapy with monoclonal antibody C595 and docetaxel in several ovarian cell cancers [19], but there are no data about combined therapy platinum compounds with anti-MUC1 in breast cancer cell lines. This evidence concerns the gene MUC1 and breast carcinoma.